Stock Track | Zai Lab Soars 5.25% Intraday on Clinical Collaboration with Boehringer Ingelheim

Stock Track04-20

Zai Lab's stock soared 5.25% during intraday trading on Monday, following the announcement of a clinical collaboration with global pharmaceutical giant Boehringer Ingelheim.

The companies will co-develop an innovative dual DLL3-targeted drug combination therapy, involving Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan and Boehringer Ingelheim's DLL3/CD3 T-cell engager obrixtamig. The Phase Ib/II study will evaluate safety, tolerability, and preliminary clinical activity, with Boehringer Ingelheim sponsoring and overseeing operations.

Additionally, Zai Lab is entering a key commercialization phase, with multiple pipeline products including the novel non-dopamine mechanism schizophrenia drug KarXT expected to drive revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134867019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134867019","market":"nz","top_or_hot":-1,"title":"Stock Track | Zai Lab Soars 5.25% Intraday on Clinical Collaboration with Boehringer Ingelheim","media":"Stock Track","content":"<p>Zai Lab's stock soared 5.25% during intraday trading on Monday, following the announcement of a clinical collaboration with global pharmaceutical giant Boehringer Ingelheim.</p><p>The companies will co-develop an innovative dual DLL3-targeted drug combination therapy, involving Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan and Boehringer Ingelheim's DLL3/CD3 T-cell engager obrixtamig. The Phase Ib/II study will evaluate safety, tolerability, and preliminary clinical activity, with Boehringer Ingelheim sponsoring and overseeing operations.</p><p>Additionally, Zai Lab is entering a key commercialization phase, with multiple pipeline products including the novel non-dopamine mechanism schizophrenia drug KarXT expected to drive revenue growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zai Lab Soars 5.25% Intraday on Clinical Collaboration with Boehringer Ingelheim</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zai Lab Soars 5.25% Intraday on Clinical Collaboration with Boehringer Ingelheim\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-20 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab's stock soared 5.25% during intraday trading on Monday, following the announcement of a clinical collaboration with global pharmaceutical giant Boehringer Ingelheim.</p><p>The companies will co-develop an innovative dual DLL3-targeted drug combination therapy, involving Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan and Boehringer Ingelheim's DLL3/CD3 T-cell engager obrixtamig. The Phase Ib/II study will evaluate safety, tolerability, and preliminary clinical activity, with Boehringer Ingelheim sponsoring and overseeing operations.</p><p>Additionally, Zai Lab is entering a key commercialization phase, with multiple pipeline products including the novel non-dopamine mechanism schizophrenia drug KarXT expected to drive revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1134867019","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134867019","pubTimestamp":1776649399,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zai Lab's stock soared 5.25% during intraday trading on Monday, following the announcement of a clinical collaboration with global pharmaceutical giant Boehringer Ingelheim.The companies will...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"个股追踪|再鼎医药盘中大涨5.25%与勃林格殷格翰临床合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"Zai Lab's stock soared 5.25% during intraday trading on Monday, following the announcement of a clinical collaboration with global pharmaceutical giant Boehringer Ingelheim.The companies will co-develop an innovative dual DLL3-targeted drug combination therapy, involving Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan and Boehringer Ingelheim's DLL3/CD3 T-cell engager obrixtamig. The Phase Ib/II study will evaluate safety, tolerability, and preliminary clinical activity, with Boehringer Ingelheim sponsoring and overseeing operations.Additionally, Zai Lab is entering a key commercialization phase, with multiple pipeline products including the novel non-dopamine mechanism schizophrenia drug KarXT expected to drive revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134867019","isCrawlerRequest":true}